RxDoctor Payments Data

J Elliott, PA

Medical · Lansing, MINPI 1841299617

Payments from drug & device makers

$6,239in general payments, 2019–2025

Across 349 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$820
  • Lilly USA, LLC$568
  • AbbVie$547
  • Amgen$523
  • Sanofi$465
  • Dermavant Sciences, Inc.$435
  • plus $3K from 15 others

What the payments were for

  • Food & beverage$5,95195%
  • Education$2885%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,239 in reported general payments places this provider in the 90th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Medicare billing

Part B allowed, 2024
$81,379
Medicare patients
338
Services billed
2,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnbrelEtanercept15$108,611
Dupixent PenDupilumab28$107,099
OtezlaApremilast21$100,318
Clobetasol Propionate149$5,890
Clindamycin Phosphate67$3,488
Fluorouracil54$3,206
Betamethasone Dipropionate66$3,057
Ciclopirox45$2,002
Azelaic Acid14$1,704
Metronidazole16$1,641
Desonide30$1,009
Triamcinolone Acetonide92$957
CiclopiroxCiclopirox Olamine70$907
Ketoconazole48$877
Doxycycline Hyclate51$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$523$208,92936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 755 medical providers in Michigan.

Other medical in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →